Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Fibrin Sealant Grifols

Plasma-derived product · developed by Instituto Grifols

Phase 3 Most advanced trial (none active)
GRFS Developer
1 Registered trials

What is Fibrin Sealant Grifols?

Fibrin Sealant Grifols is a topical product applied by drip or spray to surgical sites. It is studied in excessive bleeding during surgery.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
FS Grifols
Drug type
Plasma-derived product
Therapy area
Hematology
Developer
Instituto Grifols, S.A. (GRFS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03461406 Phase 3 Excessive Bleeding During Surgery Completed GRFS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Excessive Bleeding During Surgery

More from Instituto Grifols

albumin human, USP FDA approved Antithrombin III FDA approved factor VIII / von Willebrand factor FDA approved Alpha-1 Phase 3 C19-IG Phase 3 GRF312 Phase 2 Human Plasma-Derived Fibrinogen Concentrate Phase 1/2 IVIG-PEG Phase 3 plasma-derived FVIII/VWF concentrate Phase 4

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the GRFS page.

Follow GRFS, the company behind Fibrin Sealant Grifols

See GRFS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GRFS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.